Tests home telerehabilitation for adults receiving CAR-T therapy for lymphoma or myeloma

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with lymphoma or myeloma who are planning to have commercial CAR-T cell treatment. They would do a home-based exercise and nutrition program guided online.

Age

Older than 21 years.

Sex

All sexes can join.

Disease stage

Confirmed lymphoma or myeloma. Daily activity level (ECOG performance status) of 0-2.

Earlier treatment

Commercial FDA-approved CAR-T treatment must be planned for at least 4 weeks after joining.

Main reasons for not taking part

• Unstable angina, uncontrolled high blood pressure, or a recent heart attack
• A pacemaker
• Painful or unstable bone metastases, or recent bone fractures
• Already in a regular exercise rehabilitation program
• Plans to move within the next 6 months, or taking part in another clinical trial

The registry criteria, word for word

What the trial wants to find out

The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.

The group in the trial

• Multimodal Cancer TelerehabilitationTreatment being tested

  Each enrolled patient will undergo a four-week multimodal prehabilitation before the commencement of the CAR-T therapy. During CAR-T therapy, the patients will use an interactive app supporting cancer self-care education and early mobilization while undergoing chemotherapy, infusion, in-hospital toxicity monitoring, and recovery (the duration depends on the specific CAR-T treatment regimen). After completion of the CAR-T procedures and hospital discharge, the patients will undergo a 12-week home-based multimodal telerehabilitation. Individualized rehabilitation plans using a web-based care management portal. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment.

  Treatment: Home Automated Telemanagement (HAT) Patient Unit